Literature DB >> 20810469

Modafinil reverses phencyclidine-induced deficits in cognitive flexibility, cerebral metabolism, and functional brain connectivity.

Neil Dawson1, Rhiannon J Thompson, Allan McVie, David M Thomson, Brian J Morris, Judith A Pratt.   

Abstract

OBJECTIVE: In the present study, we employ mathematical modeling (partial least squares regression, PLSR) to elucidate the functional connectivity signatures of discrete brain regions in order to identify the functional networks subserving PCP-induced disruption of distinct cognitive functions and their restoration by the procognitive drug modafinil.
METHODS: We examine the functional connectivity signatures of discrete brain regions that show overt alterations in metabolism, as measured by semiquantitative 2-deoxyglucose autoradiography, in an animal model (subchronic phencyclidine [PCP] treatment), which shows cognitive inflexibility with relevance to the cognitive deficits seen in schizophrenia.
RESULTS: We identify the specific components of functional connectivity that contribute to the rescue of this cognitive inflexibility and to the restoration of overt cerebral metabolism by modafinil. We demonstrate that modafinil reversed both the PCP-induced deficit in the ability to switch attentional set and the PCP-induced hypometabolism in the prefrontal (anterior prelimbic) and retrosplenial cortices. Furthermore, modafinil selectively enhanced metabolism in the medial prelimbic cortex. The functional connectivity signatures of these regions identified a unifying functional subsystem underlying the influence of modafinil on cerebral metabolism and cognitive flexibility that included the nucleus accumbens core and locus coeruleus. In addition, these functional connectivity signatures identified coupling events specific to each brain region, which relate to known anatomical connectivity.
CONCLUSIONS: These data support clinical evidence that modafinil may alleviate cognitive deficits in schizophrenia and also demonstrate the benefit of applying PLSR modeling to characterize functional brain networks in translational models relevant to central nervous system dysfunction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20810469      PMCID: PMC3329989          DOI: 10.1093/schbul/sbq090

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  107 in total

1.  Brain activation during cognitive stimulation with the Wisconsin Card Sorting Test--a functional MRI study on healthy volunteers and schizophrenics.

Authors:  H P Volz; C Gaser; F Häger; R Rzanny; H J Mentzel; I Kreitschmann-Andermahr; W A Kaiser; H Sauer
Journal:  Psychiatry Res       Date:  1997-10-31       Impact factor: 3.222

2.  A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography.

Authors:  Steven G Potkin; Gustavo Alva; Kirsten Fleming; Ravi Anand; David Keator; Danilo Carreon; Michael Doo; Yi Jin; Joseph C Wu; James H Fallon
Journal:  Am J Psychiatry       Date:  2002-02       Impact factor: 18.112

3.  Impact of modafinil on prefrontal executive function in schizophrenia.

Authors:  Michael D Hunter; Venkatasubramanian Ganesan; Iain D Wilkinson; Sean A Spence
Journal:  Am J Psychiatry       Date:  2006-12       Impact factor: 18.112

4.  Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat.

Authors:  Samantha L McLean; Marie L Woolley; Dave Thomas; Joanna C Neill
Journal:  Psychopharmacology (Berl)       Date:  2009-07-21       Impact factor: 4.530

5.  Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex.

Authors:  E M Tunbridge; D M Bannerman; T Sharp; P J Harrison
Journal:  J Neurosci       Date:  2004-06-09       Impact factor: 6.167

6.  Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man.

Authors:  A M Owen; A C Roberts; C E Polkey; B J Sahakian; T W Robbins
Journal:  Neuropsychologia       Date:  1991       Impact factor: 3.139

7.  Role of glutamate in neuron-glia metabolic coupling.

Authors:  Pierre J Magistretti
Journal:  Am J Clin Nutr       Date:  2009-07-01       Impact factor: 7.045

8.  Difficulty overcoming learned non-reward during reversal learning in rats with ibotenic acid lesions of orbital prefrontal cortex.

Authors:  David Scott Tait; Verity J Brown
Journal:  Ann N Y Acad Sci       Date:  2007-08-14       Impact factor: 5.691

9.  Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat--a back translational study.

Authors:  Pascal Goetghebeur; Rebecca Dias
Journal:  Psychopharmacology (Berl)       Date:  2008-04-08       Impact factor: 4.530

Review 10.  Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

Authors:  Carlos Saavedra-Velez; Anna Yusim; Deepti Anbarasan; Jean-Pierre Lindenmayer
Journal:  J Clin Psychiatry       Date:  2008-11-18       Impact factor: 4.384

View more
  26 in total

1.  Subanaesthetic ketamine treatment alters prefrontal cortex connectivity with thalamus and ascending subcortical systems.

Authors:  Neil Dawson; Brian J Morris; Judith A Pratt
Journal:  Schizophr Bull       Date:  2011-11-22       Impact factor: 9.306

Review 2.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

Review 3.  Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.

Authors:  Maria R Dauvermann; Graham Lee; Neil Dawson
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

4.  Subchronic memantine induced concurrent functional disconnectivity and altered ultra-structural tissue integrity in the rodent brain: revealed by multimodal MRI.

Authors:  S Sekar; E Jonckers; M Verhoye; R Willems; J Veraart; J Van Audekerke; J Couto; M Giugliano; K Wuyts; S Dedeurwaerdere; J Sijbers; C Mackie; L Ver Donck; T Steckler; A Van der Linden
Journal:  Psychopharmacology (Berl)       Date:  2013-01-25       Impact factor: 4.530

5.  Brain functional connectivity of male patients in remission after the first episode of schizophrenia.

Authors:  Tomas Kasparek; Radovan Prikryl; Jitka Rehulova; Radek Marecek; Michal Mikl; Hana Prikrylova; Jiri Vanicek; Eva Ceskova
Journal:  Hum Brain Mapp       Date:  2013-03       Impact factor: 5.038

6.  Modafinil attenuates inflammation via inhibiting Akt/NF-κB pathway in apoE-deficient mouse model of atherosclerosis.

Authors:  Jinxia Han; Dongwei Chen; Dayi Liu; Yanan Zhu
Journal:  Inflammopharmacology       Date:  2017-08-21       Impact factor: 4.473

7.  Modulation of fronto-cortical activity by modafinil: a functional imaging and fos study in the rat.

Authors:  Alessandro Gozzi; Valeria Colavito; Paul F Seke Etet; Dino Montanari; Silvia Fiorini; Stefano Tambalo; Angelo Bifone; Gigliola Grassi Zucconi; Marina Bentivoglio
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

Review 8.  The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia.

Authors:  Sanna K Janhunen; Heta Svärd; John Talpos; Gaurav Kumar; Thomas Steckler; Niels Plath; Linda Lerdrup; Trine Ruby; Marie Haman; Roger Wyler; Theresa M Ballard
Journal:  Psychopharmacology (Berl)       Date:  2015-06-14       Impact factor: 4.530

9.  A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia.

Authors:  Laura Christina Wittkampf; Johannes Arends; Leo Timmerman; Marike Lancel
Journal:  Ther Adv Psychopharmacol       Date:  2012-06

10.  Subanesthetic ketamine treatment promotes abnormal interactions between neural subsystems and alters the properties of functional brain networks.

Authors:  Neil Dawson; Martin McDonald; Desmond J Higham; Brian J Morris; Judith A Pratt
Journal:  Neuropsychopharmacology       Date:  2014-02-04       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.